ClinicalTrials.gg
Active, not recruitingNCT04461639HA-SAFEUpdated Jul 1, 2026

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

An observational study in Hemophilia A, sponsored by Bayer. Active, not recruiting at 6 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Bayer · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Enrollment
15th of 26
62 · median 67
Started
2021
with 1 other
Observational
26 of 57
3 open now
Registered
49th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 15th largest by enrollment of the 26 observational ones that give a count, is one of 2 that started in 2021, is one of 26 observational ones, and was the 49th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the treatment of hemophilia A (bleeding disorder resulting from a lack of FVIII). It is manufactured via recombinant technology and has an extended half-live, i.e. it will stay longer in the body than other FVIII products. Therefore Jivi acts longer in the body which reduces the frequency of drug injections. This study will enroll previously treated patients with hemophilia A who are receiving Jivi regularly at their treating doctors to prevent bleeding. Observation for each patient will last for at least 4 years, and medical data will be collected during patients' routine visits at their treating doctors.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All previously treated patients (PTPs) with hemophilia A receiving prophylaxis with damoctocog alfa pegol will be eligible to be enrolled in the study. Indications and contra-indications according to the local market authorization will be carefully considered

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed /assent will be obtained before any study-related activities
  • PTPs with hemophilia A assigned to Jivi prophylaxis treatment
  • Negative FVIII inhibitor test before study entry
  • Decision to initiate treatment with commercially available Jivi has been made by the treating physician before and independently from the decision to include the patient in this study

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to Jivi or related products
  • Mental incapacity, unwillingness or other barriers precluding adequate understanding or cooperation
  • Participation in an program with interventions outside of routine clinical practice
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (actual)
Patient registry
No

Groups and cohorts

  • Damoctocog alfa pegol

    Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.

    Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)

Interventions

  • DrugDamoctocog alfa pegolStudies of Damoctocog alfa pegolDamoctocog alfa pegol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice

06

What researchers measure

Primary outcomes

  1. Number of participants with safety events

    Time frame: At least 4 years

  2. Duration of safety events

    Time frame: At least 4 years

  3. Number of participants with safety events leading to a change of treatment

    Time frame: At least 4 years

  4. Number of participants with safety events per intensity

    The maximum intensity of each safety event should be assigned to one of the following categories: mild, moderate or severe

    Time frame: At least 4 years

  5. Number of participants with safety events with outcome of death

    Time frame: At least 4 years

  6. Number of participants with safety events related to inhibitor development

    Time frame: At least 4 years

Secondary outcomes

  1. Number of adverse reactions (ARs) that are defined within the system organ classes nervous system and psychiatric disorders

    Time frame: At least 4 years

  2. Number of adverse reactions (ARs) related to hepatic or renal function

    Time frame: At least 4 years

  3. Change from baseline in creatinine

    Time frame: At least 4 years

  4. Change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: At least 4 years

  5. Change from baseline in alanine transaminase (ALT)

    Time frame: At least 4 years

  6. Change from baseline in aspartate aminotransferase (AST)

    Time frame: At least 4 years

  7. Change from baseline in bilirubin

    Time frame: At least 4 years

  8. Testing for PEG plasma levels (baseline and end of study)

    PEG (Polyethylene Glycol)-plasma levels at baseline and end of study will be analyzed only if PEG-plasma levels were collected in local routine clinical practice at the investigator's discretion.

    Time frame: At least 4 years

  9. Number of patients with abnormal findings as assessed by neurological examination

    Time frame: At least 4 years

07

Study locations

6 sites
  • Many Locations
    Multiple Locations, Austria
  • Many Locations
    Multiple Locations, Germany
  • Many Locations
    Multiple Locations, Greece
  • Many Locations
    Multiple Locations, Italy
  • Many Locations
    Multiple Locations, Slovenia
  • Many Locations
    Multiple Locations, Spain
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Mar 2027, 70 months after the start.

Of 53 industry-sponsored observational studies under Hemophilia A, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 79. This study's planned 70 months is above that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jul 8, 2020
StartActual
May 14, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04461639
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 8, 2020
Start date
May 14, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion